Analyst Activity – HC Wainwright Initiates Coverage On Agile Therapeutics (NASDAQ:AGRX) With a Buy

ME Staff
-
0

Analyst Ratings For Agile Therapeutics (NASDAQ:AGRX)

Today, HC Wainwright initiated coverage on Agile Therapeutics (NASDAQ:AGRX) with a Buy with a price target of $10.00.

There are 6 buy ratings on the stock.

The current consensus rating on Agile Therapeutics (NASDAQ:AGRX) is Buy (Score: 3.00) with a consensus target price of $11.17 per share, a potential 167.79% upside.

Some recent analyst ratings include

  • 7/19/2017-HC Wainwright initiated coverage with a Buy rating.
  • 6/14/2017-Noble Financial Reiterated Rating of Buy.
  • 5/8/2017-Cantor Fitzgerald Reiterated Rating of Buy.
  • 1/5/2017-Janney Montgomery Scott Reiterated Rating of Buy.
  • 11/10/2015-William Blair Reiterated Rating of Buy.

Recent Insider Trading Activity For Agile Therapeutics (NASDAQ:AGRX)
Agile Therapeutics (NASDAQ:AGRX) has insider ownership of 3.50% and institutional ownership of 79.78%.

  • On 5/11/2017 Alfred Altomari, Chairman, bought 10,000 with an average share price of $3.51 per share and the total transaction amounting to $35,100.00. View SEC Filing
  • On 5/11/2017 Renee Selman, Insider, bought 53,333 with an average share price of $3.68 per share and the total transaction amounting to $196,265.44. View SEC Filing
  • On 1/27/2016 Jay Moorin, Major Shareholder, bought 393,700 with an average share price of $6.35 per share and the total transaction amounting to $2,499,995.00. View SEC Filing
  • On 6/2/2015 Alfred Altomari, CEO, bought 2,500 with an average share price of $8.73 per share and the total transaction amounting to $21,825.00. View SEC Filing
  • On 1/23/2015 Jay Moorin, Major Shareholder, bought 811,966 with an average share price of $5.85 per share and the total transaction amounting to $4,750,001.10. View SEC Filing
  • On 5/29/2014 Care Capital Iii Llc, Major Shareholder, bought 500,000 with an average share price of $6.00 per share and the total transaction amounting to $3,000,000.00. View SEC Filing
  • On 5/23/2014 Andrew N Schiff, Director, bought 1,333,333 with an average share price of $6.00 per share and the total transaction amounting to $7,999,998.00. View SEC Filing

Recent Trading Activity for Agile Therapeutics (NASDAQ:AGRX)
Shares of Agile Therapeutics closed the previous trading session at 4.17 down -0.01 -0.24% with 103,476 shares trading hands.